Saturday 17 October 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADX Healthcare Biotechnology
Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
1.03
0.05
−4.63%
Follow RADX
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
3.37 | 2.67 | 3.01 | 1.16 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Intangible Assets out of Total Assets |
0.52 | 0.54 | 0.49 | 0.63 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(14.47) | (23.73) | (14.88) | (35.82) | |
Working Capital |
20.33 | 16.14 | 20.18 | 2.06 | |
Capital Expenditures |
1.95 | 0.00 | — | — | |
Net Current Asset Value |
2.54 | (2.43) | 3.16 | (10.78) | |
| Other line items | |||||
Quick Ratio |
3.25 | 2.65 | 3.00 | 1.14 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | — | |
Average Receivables |
— | — | — | 6.25 | |
Average Payables |
— | — | — | 7.13 | |
Average Assets |
— | — | — | 44.03 | |
Average Common Equity |
— | — | — | 16.54 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 16 Oct 2026